Most NF1 mutations were exclusive of KRAS and EGFR mutation (19 of the 24 samples), and one third co‐occurred with TP53. These results are consistent with previous published studies.14, 23, 24 However, the occurrence of NF1 mutations was higher in our study (17.5%) compared to the study by Redig et al (10%).14 The population of these two studies was different: Redig et al study described patients with metastatic adenocarcinomas and squamous cell cancers and our cohort only included patients with metastatic adenocarcinoma. Here, KRAS is linked to squamous cell carcinoma.